DKM 2-93

65836-72-8

C11H14ClNO3

DMSO : >= 150 mg/mL (615.54 mM)

Metabolic Enzyme/Protease

DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC₅₀ of 430 uM. IC50 & Target: IC50: 430 uM (UBA5), 90 uM (PaCa2 cells), 30 uM (Panc1 cells)^[1] In Vitro: Ubiquitin-like modifier activating enzyme 5 (UBA5) is a novel pancreatic cancer therapeutic target. DKM 2-93 impairs pancreatic cancer cell survival through covalently modifying the catalytic cysteine of UBA5, thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins. DKM 2-93 inhibits PaCa2 and Panc1 cells survival with IC₅₀s of 90 and 30 uM, respectively^[1]. In Vivo: DKM 2-93 daily treatment significantly impairs tumor growth of PaCa2 cells in vivo in tumor xenograft studies in immune-deficient mice without causing any weight loss or overt toxicity^[1].